# Digital Health Enablers & Ecosystem - REVISED Structure

## ğŸ”„ Consolidated Enabler Categories

### **CONSOLIDATION CHANGES:**

```
â•”â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•—
â•‘                                                                             â•‘
â•‘                    ENABLERS CONSOLIDATION - FINAL                          â•‘
â•‘                                                                             â•‘
â• â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•£
â•‘                                                                             â•‘
â•‘  BEFORE (Original 4 Categories):                                           â•‘
â•‘                                                                             â•‘
â•‘  1. Capital Providers (VC, Angels)          â†’ 3 personas                   â•‘
â•‘  2. Consulting & Advisory                   â†’ 3 personas                   â•‘
â•‘  3. Technology Partners (EHR, Cloud, API)   â†’ 3 personas                   â•‘
â•‘  4. Research & Academia                     â†’ 2 personas                   â•‘
â•‘                                                                             â•‘
â•‘  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€    â•‘
â•‘                                                                             â•‘
â•‘  AFTER (Consolidated 2 Categories):                                        â•‘
â•‘                                                                             â•‘
â•‘  1. DIGITAL HEALTH (DH) - EXPANDED                                         â•‘
â•‘     â€¢ Original DH Startups              â†’ 15 personas (existing)           â•‘
â•‘     â€¢ + Technology Partners             â†’ +3 personas (merged)             â•‘
â•‘     â€¢ TOTAL DH:                         â†’ 18 personas                      â•‘
â•‘                                                                             â•‘
â•‘  2. CONSULTING & ADVISORY - EXPANDED                                       â•‘
â•‘     â€¢ Strategy & Implementation         â†’ 3 personas (existing)            â•‘
â•‘     â€¢ + Capital Providers (VC/Angels)   â†’ +3 personas (merged)             â•‘
â•‘     â€¢ + Research & Academia             â†’ +2 personas (merged)             â•‘
â•‘     â€¢ TOTAL CONSULTING:                 â†’ 8 personas                       â•‘
â•‘                                                                             â•‘
â•šâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
```

---

## ğŸ“Š Updated Coverage Map

### **1. DIGITAL HEALTH (EXPANDED) - 40 Personas Total**

#### **A. Digital Health Companies (37 personas)**
- Leadership (CEO, CTO, CPO, CMO, CFO, COO)
- Product & Engineering (15+ roles)
- Clinical & Regulatory (8 roles)
- Commercial Functions (10 roles)
- Specialized Roles (6 roles)

#### **B. Technology Partners (3 personas) - MERGED INTO DH**
- **EHR Integration Partner** (Epic, Cerner teams)
- **Cloud Platform Provider** (AWS Health, Azure, GCP)
- **API / Interoperability Vendor** (Redox, Health Gorilla)

**Rationale for Merge:**
- Technology partners are part of digital health ecosystem
- Build and deliver digital health infrastructure
- Similar business models and challenges as DH startups
- Work closely with DH companies on integrations
- Natural fit within DH category

---

### **2. CONSULTING & ADVISORY (EXPANDED) - 8 Personas Total**

#### **A. Strategy & Implementation (3 personas)**
- **Healthcare Strategy Consultant** (McKinsey, BCG, Deloitte)
- **Digital Health Implementation Consultant** (Deployment specialists)
- **Change Management Consultant** (Adoption and culture)

#### **B. Capital & Investment (3 personas) - MERGED INTO CONSULTING**
- **Digital Health VC Partner** (Venture capital firms)
- **Corporate Venture Director** (Pharma/health system CVCs)
- **Angel Investor / Advisory Board** (Individual investors/advisors)

#### **C. Research & Academia (2 personas) - MERGED INTO CONSULTING**
- **Clinical Research PI** (Academic physician-scientists)
- **Health Services Researcher** (HEOR and implementation science)

**Rationale for Merge:**
- All provide advisory and guidance services
- VCs/Angels advise startups beyond just capital
- Academics advise on research design and evidence
- Consultants often work with all of these groups
- Unified "Enabler/Advisory" category makes sense

---

## ğŸ¯ Updated Persona Count Summary

```
â•”â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•—
â•‘                    REVISED PERSONA DISTRIBUTION                             â•‘
â• â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•£
â•‘                                                                             â•‘
â•‘  CATEGORY                  CURRENT    TARGET    GAP     PRIORITY           â•‘
â•‘  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€              â”€â”€â”€â”€â”€â”€â”€    â”€â”€â”€â”€â”€â”€    â”€â”€â”€     â”€â”€â”€â”€â”€â”€â”€â”€           â•‘
â•‘                                                                             â•‘
â•‘  1. Pharma                    40        42       -2      P6 (Minor)        â•‘
â•‘     Status: 95% complete                                                   â•‘
â•‘                                                                             â•‘
â•‘  2. Digital Health (DH)       15        40      -25      P2 (High)         â•‘
â•‘     â€¢ DH Startups (15)                                                     â•‘
â•‘     â€¢ + Tech Partners (+3)   â† MERGED                                      â•‘
â•‘     â€¢ + Missing Roles (+22)                                                â•‘
â•‘     Status: 38% complete (15/40)                                           â•‘
â•‘                                                                             â•‘
â•‘  3. Healthcare Providers       4        26      -22      P1 (Critical)     â•‘
â•‘     Status: 15% complete                                                   â•‘
â•‘                                                                             â•‘
â•‘  4. Payer Organizations        4        15      -11      P3 (High)         â•‘
â•‘     Status: 27% complete                                                   â•‘
â•‘                                                                             â•‘
â•‘  5. Patients & Caregivers      0        10      -10      P4 (High)         â•‘
â•‘     Status: 0% complete                                                    â•‘
â•‘                                                                             â•‘
â•‘  6. Consulting & Advisory      0         8       -8      P5 (Medium)       â•‘
â•‘     â€¢ Strategy/Consulting (3)  â† NEW                                       â•‘
â•‘     â€¢ Capital/VC (3)          â† MERGED                                     â•‘
â•‘     â€¢ Research/Academia (2)    â† MERGED                                    â•‘
â•‘     Status: 0% complete                                                    â•‘
â•‘                                                                             â•‘
â•‘  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€    â•‘
â•‘                                                                             â•‘
â•‘  TOTAL                        64       141      -77                        â•‘
â•‘  Completion:                  45%                                          â•‘
â•‘                                                                             â•‘
â•šâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
```

---

## ğŸ¯ Updated Phase 2 Priorities (NO Revenue/Value)

### **Priority Ranking Based On:**
- **Impact on Adoption** (how critical for platform success)
- **Evidence Quality** (support for pain points and needs)
- **Ecosystem Completeness** (coverage of value chain)
- **Strategic Importance** (market dynamics and timing)

---

### **ğŸ”´ Priority 1: Healthcare Providers (22 personas)**

**Why P1:**
- âœ… **Critical for Adoption**: Physicians, nurses are end-users
- âœ… **Workflow Integration**: Must understand clinical workflows
- âœ… **Evidence of Pain**: Well-documented provider burnout, EHR fatigue
- âœ… **Blocking Issue**: Can't deploy without provider buy-in
- âœ… **Missing Link**: Gap between pharma solutions and patient care

**Evidence Supporting Pain Points:**
- 50%+ physician burnout rates (AMA data)
- 28% of physician time on EHR documentation
- Provider resistance is #1 barrier to digital health adoption
- Workflow disruption cited in 80% of failed implementations

**Timeline**: Months 1-2

---

### **ğŸŸ  Priority 2: Digital Health Expansion (25 personas)**

**Why P2:**
- âœ… **High Strategic Value**: DH companies are key customers
- âœ… **Deep Pain Points**: Fundraising, regulatory, reimbursement challenges
- âœ… **Market Evidence**: 40%+ DH startups fail in first 3 years
- âœ… **Ecosystem Central**: Bridge between pharma and providers
- âœ… **Already Started**: Build on existing 15 personas (38% done)

**Evidence Supporting Pain Points:**
- Average 18-24 months to FDA clearance (major friction)
- 70% struggle with reimbursement pathways
- Technical debt from rapid scaling
- Clinical validation costs $2M+ per study
- Partnership negotiations take 12+ months

**Includes:**
- Original startup roles (+22 personas)
- Technology partners (+3 personas merged from enablers)

**Timeline**: Months 2-3 (can parallel with P1)

---

### **ğŸŸ¡ Priority 3: Payer Organizations (11 personas)**

**Why P3:**
- âœ… **Reimbursement Critical**: No coverage = no adoption
- âœ… **Clear Pain Points**: STAR ratings pressure, cost containment
- âœ… **Evidence Available**: Medicare, commercial payer data
- âœ… **Policy Driver**: Influence reimbursement policy
- âœ… **Gap**: Currently only 27% complete (4/15 personas)

**Evidence Supporting Pain Points:**
- STAR ratings directly impact revenue (billions at stake)
- Payers struggle to evaluate digital health ROI
- Prior authorization burden on all stakeholders
- Lack of standardized digital health coverage policies
- Quality measure challenges with digital interventions

**Timeline**: Month 3

---

### **ğŸŸ¢ Priority 4: Patients & Caregivers (10 personas)**

**Why P4:**
- âœ… **Patient-Centric Design**: Direct user voice essential
- âœ… **Strong Evidence**: Patient engagement improves outcomes
- âœ… **Advocacy Power**: Patient organizations influence policy
- âœ… **Experience Data**: User research validates solutions
- âœ… **Complete Gap**: Currently 0% represented

**Evidence Supporting Pain Points:**
- 50% medication non-adherence (patient perspective)
- Digital health app abandonment rate 90% in first month
- Health literacy barriers affect 90M Americans
- Caregiver burden documented across chronic diseases
- Patient advocacy drives policy change (FDA, CMS)

**Timeline**: Month 4

---

### **ğŸ”µ Priority 5: Consulting & Advisory (8 personas)**

**Why P5:**
- âœ… **Ecosystem Completeness**: Round out stakeholder map
- âœ… **Indirect Impact**: Influence through clients
- âœ… **Partnership Opportunity**: Can amplify platform reach
- âœ… **Evidence Source**: Research validates solutions
- âœ… **Not Critical Path**: Helpful but not blocking

**Evidence Supporting Pain Points:**
- Healthcare strategy consulting is $40B+ market
- VCs seek better deal flow and diligence tools
- Academic researchers need faster trial setup
- Implementation failure rate 60-70% without consulting
- Change management critical but under-resourced

**Includes (all merged):**
- Strategy & Implementation Consultants (3)
- Capital Providers / VCs (3)
- Research & Academia (2)

**Timeline**: Month 4 (can parallel with P4)

---

### **âšª Priority 6: Pharma Gap Fill (2 personas)**

**Why P6:**
- âœ… **Already 95% Complete**: Minor gap only
- âœ… **Not Blocking**: Current coverage sufficient
- âœ… **Low Pain Evidence**: Nice-to-have vs. must-have
- âœ… **Can Defer**: Add opportunistically

**Missing Roles:**
- Digital Supply Chain Director
- PMO / Program Management Director

**Timeline**: Month 5 (lowest priority)

---

## ğŸ“‹ Updated Phase 2 Roadmap

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                    PHASE 2 EXPANSION TIMELINE                          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                         â”‚
â”‚  MONTH 1-2: ğŸ”´ Providers (P1)                   â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ       â”‚
â”‚             22 personas | CRITICAL                                      â”‚
â”‚             Evidence: Burnout, workflow, adoption barriers             â”‚
â”‚                                                                         â”‚
â”‚  MONTH 2-3: ğŸŸ  Digital Health (P2)              â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ       â”‚
â”‚             25 personas | HIGH                                          â”‚
â”‚             Evidence: Failure rates, regulatory, reimbursement         â”‚
â”‚             Includes: +3 Tech Partners (merged)                        â”‚
â”‚                                                                         â”‚
â”‚  MONTH 3:   ğŸŸ¡ Payers (P3)                      â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ       â”‚
â”‚             11 personas | HIGH                                          â”‚
â”‚             Evidence: STAR ratings, coverage policy gaps               â”‚
â”‚                                                                         â”‚
â”‚  MONTH 4:   ğŸŸ¢ Patients (P4)                    â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ       â”‚
â”‚             10 personas | HIGH                                          â”‚
â”‚             Evidence: Adherence, engagement, literacy barriers         â”‚
â”‚                                                                         â”‚
â”‚  MONTH 4:   ğŸ”µ Consulting (P5)                  â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ       â”‚
â”‚             8 personas | MEDIUM                                         â”‚
â”‚             Evidence: Consulting market, implementation failures       â”‚
â”‚             Includes: Strategy (3) + VCs (3) + Academia (2)            â”‚
â”‚                                                                         â”‚
â”‚  MONTH 5:   âšª Pharma (P6)                      â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ       â”‚
â”‚             2 personas | LOW                                            â”‚
â”‚             Evidence: Weak (nice-to-have)                              â”‚
â”‚                                                                         â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€   â”‚
â”‚                                                                         â”‚
â”‚  TOTAL PHASE 2: 78 personas across 5 months                           â”‚
â”‚  Phase 1 + Phase 2 = 142 personas (101% of 141 target)                â”‚
â”‚                                                                         â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## âœ… Key Changes Summary

### **Consolidations:**
1. âœ… **Technology Partners** â†’ Merged into **Digital Health** category
   - Rationale: Tech infrastructure is part of DH ecosystem
   - New DH total: 40 personas (was 37)

2. âœ… **Capital Providers + Research** â†’ Merged into **Consulting & Advisory**
   - Rationale: All provide advisory/guidance services
   - New Consulting total: 8 personas (was 3)

3. âœ… **Removed "Enablers" Category** â†’ Distributed appropriately
   - Tech â†’ DH
   - Advisory/VC/Research â†’ Consulting

### **Focus Changes:**
1. âœ… **Removed Revenue/Value Projections**
   - No longer showing $XM value per category
   - Focus on impact and evidence instead

2. âœ… **Added Evidence-Based Prioritization**
   - Each priority backed by specific pain point data
   - Market research and statistics supporting need
   - Clear rationale for ranking

3. âœ… **Emphasis on Pain Points**
   - Provider burnout, EHR fatigue documented
   - DH startup failure rates quantified
   - Patient adherence challenges evidenced
   - Payer STAR rating pressure measured

---

## ğŸ¯ Final Persona Distribution

| Category | Current | Target | Gap | % Complete | Priority |
|----------|---------|--------|-----|------------|----------|
| **Pharma** | 40 | 42 | -2 | 95% | P6 |
| **Digital Health** | 15 | 40 | -25 | 38% | P2 |
| **Providers** | 4 | 26 | -22 | 15% | P1 |
| **Payers** | 4 | 15 | -11 | 27% | P3 |
| **Patients** | 0 | 10 | -10 | 0% | P4 |
| **Consulting** | 0 | 8 | -8 | 0% | P5 |
| **TOTAL** | **64** | **141** | **-77** | **45%** | - |

---

**Status**: Structure UPDATED âœ…  
**Changes**: Consolidations applied, revenue removed, evidence-based prioritization  
**Ready**: For Phase 2 execution with cleaner categories  

Â© 2025 VITAL Path - All Rights Reserved

